✨ What is MAGIC and why does it matter for gene therapy?

PI
@SaverioTedesco
shares how this multi-partner project tackles key challenges in rare neuromuscular conditions – building building tools for safer, more effective treatments.

🎥 Watch below

#GeneTherapy #RareDisease

Last month, MAGIC partners met in Lisbon for our annual General Assembly at GIMM.

Discussions focused on:
• Improving AAV delivery for gene therapy
• Gene editing beyond mutation correction
• 3D muscle models to accelerate testing

Read more: magic-horizon.eu/news/magic-g...

🔬 Curious about the latest progress in gene therapy for muscular dystrophies?

The #MAGICproject is publishing impactful research, scientific tools & resources for the wider community.

🧬 Explore open-access papers, abstracts, and key findings here:

👉 magic-horizon.eu

What’s next for gene therapy?

Our workshop brought researchers together for a Q&A with MAGIC experts Eduard Ayuso, David-Alexandre Gross, Gabriela Silve & Odile Boespflug-Tanguy.

From delivery challenges to emerging tech, the future looks bold.

#GeneTherapy

Proud to host today’s MAGIC Project workshop in Lisbon, where experts are discussing:

🔬Muscle on a Chip
🧬Gene Editing
💉Viral Transduction
🧫Vector Production

We're sharing knowledge with the wider research community to accelerate progress in #genetherapy.

🚨 MAGIC Project General Assembly! 🚨

Consortium partners are gathering to:

✅ Share progress
✅ Strengthen collaboration
✅ Align on next steps

We’re driving innovation in neuromuscular disease & gene therapy – and building momentum for the year ahead. 🚀

#ResearchProgress

🔬 Earlier this month at #ESGCT2025, MAGIC partners
@crick.ac.uk
shared 3 posters on human models for neuromuscular gene therapy:

🧪 3D cultures for DMD
🧠 AAV dynamics in multi-organoids
🧬 Myotubular myopathy modelling

Pushing boundaries in patient-relevant research.

#genetherapy #MagicProject

New #PNAS paper: Lymphatic dysfunction is linked to disease pathogenesis in Duchenne muscular dystrophy animal models. #Myoblue tinyurl.com/4anzhr3u

Myopathie de Duchenne : une nouvelle étape déterminante vient d’être franchie ! @genethonfr.bsky.social annonce avoir obtenu les autorisations pour démarrer la phase pivot de son essai clinique de thérapie génique avec son candidat-médicament GNT0004

Notre actu www.afm-telethon.fr/fr/actualite...

🧬 La molécule TYRA-300, développée par le laboratoire de la Dr Laurence Legeai-Mallet et Tyra Biosciences, cible les troubles liés au gène FGFR3. Elle stimule la croissance osseuse sans effet secondaire.

Prochaine étape : étude clinique chez l'enfant.

👉 En savoir plus : www.institutimagine.org/fr

New #MolTherapy paper: AAV-microutrophin gene therapy confers long-term cardioprotection against pharmacologic and exercise-induced injury in dystrophin deficiency. #Myoblue tinyurl.com/ypdkckmc

Interesting new #Dev_Cell paper: Microtubules coordinate mitochondria transport with myofibril morphogenesis during muscle development. #Myoblue tinyurl.com/3j29y6aw

www.sciencedirect.com/science/arti...

🇯🇵
👉Iron supplementation alleviates pathologies in a mouse model of #FSHD

💡DUX4-provoked toxicity is involved in the activation of the ferroptosis-related pathway

📰https://jci.org/articles/view/181881
(pdf) jci.org/articles/vie...

Join us on Thursday 17th July at 14:00 BST to hear June Kinoshita, Director of Research and Patient Engagement, FSHD Society, talk about her impactful work with the FSHD Alliance.

Sign up to join the virtual session on our website: www.worldmusclesociety.org/m/events/vie...

Analyses of one of the world’s largest protein datasets offer new insights into the biological underpinnings of major neurodegenerative diseases, according to research presented by the Global Neurodegeneration Proteomics Consortium (GNPC) in Nature Medicine and Nature Aging. #medsky 🧪

Hello Bluesky! #London